Working… Menu

Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00051909
Recruitment Status : Completed
First Posted : January 20, 2003
Last Update Posted : July 19, 2006
Information provided by:
Eli Lilly and Company

Brief Summary:
Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: LY451395 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
Study Start Date : November 2002
Study Completion Date : June 2003

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Must have a clinical diagnosis of Alzheimer's Disease
  • Must be at least 50 years of age
  • Must fluently read and speak English
  • Must have a reliable caregiver

Exclusion Criteria:

  • Has serious health problems other than Alzheimer's Disease
  • Cannot swallow whole pills
  • Has had a menstrual period in the last two years
  • Takes insulin for diabetes
  • Has taken Aricept, Reminyl, or Exelon in the last 5 weeks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00051909

Layout table for location information
United States, California
Beverly Hills, California, United States
Fresno, California, United States
United States, Florida
Boca Raton, Florida, United States
Fort Lauderdale, Florida, United States
Miami Beach, Florida, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
United States, Texas
Wichita Falls, Texas, United States
Sponsors and Collaborators
Eli Lilly and Company
Layout table for additonal information Identifier: NCT00051909    
Other Study ID Numbers: 6764
First Posted: January 20, 2003    Key Record Dates
Last Update Posted: July 19, 2006
Last Verified: July 2006
Keywords provided by Eli Lilly and Company:
Alzheimer's Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders